Aisling Capital Management’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,834,910
| Closed | -$1.04M | – | 15 |
|
|
2025
Q2 | $1.04M | Hold |
2,834,910
| – | – | 0.29% | 9 |
|
|
2025
Q1 | $735K | Hold |
2,834,910
| – | – | 0.25% | 10 |
|
|
2024
Q4 | $1.59M | Hold |
2,834,910
| – | – | 0.56% | 11 |
|
|
2024
Q3 | $1.7M | Hold |
2,834,910
| – | – | 0.65% | 12 |
|
|
2024
Q2 | $7.65M | Hold |
2,834,910
| – | – | 3.31% | 4 |
|
|
2024
Q1 | $14.5M | Hold |
2,834,910
| – | – | 4.92% | 4 |
|
|
2023
Q4 | $1.52M | Hold |
2,834,910
| – | – | 0.45% | 11 |
|
|
2023
Q3 | $1.88M | Hold |
2,834,910
| – | – | 0.77% | 12 |
|
|
2023
Q2 | $4.31M | Hold |
2,834,910
| – | – | 2.11% | 9 |
|
|
2023
Q1 | $5.39M | Hold |
2,834,910
| – | – | 2.59% | 6 |
|
|
2022
Q4 | $2.69M | Hold |
2,834,910
| – | – | 1.78% | 9 |
|
|
2022
Q3 | $3.2M | Hold |
2,834,910
| – | – | 2.13% | 9 |
|
|
2022
Q2 | $3.97M | Hold |
2,834,910
| – | – | 2.83% | 8 |
|
|
2022
Q1 | $7.14M | Hold |
2,834,910
| – | – | 3.86% | 7 |
|
|
2021
Q4 | $17.1M | Hold |
2,834,910
| – | – | 6.02% | 5 |
|
|
2021
Q3 | $22.1M | Hold |
2,834,910
| – | – | 4.4% | 5 |
|
|
2021
Q2 | $38.5M | Buy |
+2,834,910
| New | +$35M | 6.16% | 2 |
|
Other funds holding ELEV
Aisling Capital Management's ELEV Position: Q3 2025 in Review
Aisling Capital Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 2,834,910 shares — an estimated $1.04M sold.
Aisling Capital Management first reported a position in ELEV in Q2 2021 and held it in 17 quarters. The position peaked at $38.5M in Q2 2021. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- Aisling Capital Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- Aisling Capital Management sold 2,834,910 Elevation Oncology shares in Q3 2025, an estimated $1.04M.
- Aisling Capital Management first reported a position in Elevation Oncology in Q2 2021 and held it in 17 quarters.
- Aisling Capital Management's Elevation Oncology position peaked at $38.5M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on Aisling Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.